Reply to: “Regulatory T cells in autoimmune hepatitis”  by Peiseler, Moritz et al.
In conclusion, we would urge the authors to be more cautious
in the interpretation of their and published observations and we
agree with the editorial comment that improved methodologies
will help better understand the role of T-regs in disease.
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Reply to: ‘‘Regulatory T cells in autoimmune hepatitis’’
JOURNAL OF HEPATOLOGYTo the Editor:
We read with interest the comment by Longhi et al. on our paper
on Tregs in autoimmune hepatitis (AIH) [1] and the accompany-
ing editorial by Oo and Adams [2]. The discrepant results by
Longhi et al. and us on Treg function in autoimmune hepatitis
(AIH) may originate from the use of different methods to purify
and assess the suppressor activity of Tregs [3,4]. Therefore, we
will reply to the criticism by comparing the methodologies used
by the Kings College group and by us, and explain why we chose
the methodology as we did.
To determine Treg function, Longhi et al. used the 3H-thymi-
dine assay. First, Treg were puriﬁed with magnetic beads to
enrich CD25+ CD4+ T cells; indeed, >95% of these cells were
CD25+. These CD25+ cells were then co-cultured together with
CD25 CD4+ T cells at a ratio of 1:8 for several days, after which
3H-thymidine was added to determine proliferation of the cell
mixture. We also enriched CD25+ CD4+ T cells with magnetic
beads, and found that >95% of these cells expressed CD25. How-
ever, in humans, CD25 alone cannot be used as a marker for Treg
cells, since, in human blood, up to 30% of the CD4+ T cells can
express CD25, but only 1–2% of these are functional suppressors
[4]. In contrast to Longhi et al., we therefore further characterised
the CD25+ cells by staining Foxp3 and CD127 (Fig. 2A of our man-
uscript), demonstrating that the majority of these cells (80–90%)
were indeed Treg. More importantly, we also characterised the
CD25 effector population by showing that more than 90% of
cells were non-Tregs (Fig. 2A). We then determined Treg function
with the CFSE dilution assay, in which only CD25 CD4+ effectorJournal of Hepatology 20
Open access under CC BY-NC-ND license.T cells were labelled with CFSE and subsequently co-cultured
together with the unlabelled CD25+ Treg fraction. The great
advantage of the CFSE assay over the 3H-thymidine assay is that
it is able to speciﬁcally evaluate the proliferation of the CD25
CD4+ responder T cell population [5–7]. The 3H-thymidine assay,
in contrast, cannot distinguish which cells in the co-culture have
incorporated 3H-thymidine, which can result in false estimates of
Treg suppression [7]. In addition, unlike the CFSE assay, 3H-thy-
midine assays can only give a snapshot of proliferation for the
period of time during which 3H-thymidine was present in the
culture [7]. Moreover, unlike murine Treg cells, human Treg cells
have a tendency to proliferate after activation [4], making the dis-
tinction of those cells that actually proliferated in the culture
even more problematic. We thus would like to refer to Sakaguchi
et al. [4] who state that ‘this indicates that thymidine uptake by cul-
tured Treg and effector cells is not appropriate to assess suppressive
activity of human Treg cells’, and instead ‘propose that it is more
accurate to assess dilution of CFSE in effector T cells to determine
the percentage and number of proliferating cells’.
Another point addressed by Longhi et al. is that we cultured
Treg cells and effector cells at a ratio of 1:1, instead of 1:8 as
they did, arguing that this ratio is ‘utterly non-physiological’.
We do agree that this assay is non-physiological, as basically
any in vitro assay. However, the aim of the assay was not to
determine the Treg physiology, but to assess their suppressive
potential, which, as others have shown [5–7], can be reasonably
performed with the CFSE assay using ratios in a range between
2:1 and 1:4.12 vol. 57 j 921–934 933
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Moritz Peiseler
Marcial Sebode
Letters to the Editor
Longhi et al. further criticise our gating strategy and claim that
the Treg frequencies in peripheral blood reported by us were
vastly lower than those reported in the literature [8]; however,
in the paper they refer to, we ﬁnd a gating strategy to determine
CD25(high) cells (see Fig. 1 in that paper) that is very similar to
that used by us (see our Fig. 1A). Moreover, it is actually stated
in this paper that only ‘the top 1% of CD25-staining CD4 T cells’ con-
tain Treg cells [8], a number not vastly different from the fre-
quencies reported by us.
Longhi et al. also refer to a conference abstract, in which they
have reported that Treg cell numbers are similar in AIH patients
and healthy subjects; we apologise for having cited only previous
papers of this group, which had reported impaired Treg frequen-
cies in AIH.
Longhi et al. quote us having attributed the discrepancies
between previous ﬁndings and our report to the use of ‘improved
methodology’ to deﬁne ‘true Treg’. We would like to emphasise
that we did not use the quoted terms in our paper. Nevertheless,
we believe that the methodology used by us was appropriate and
that the conclusions drawn from these experiments are valid.Conﬂict of interest
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